{"id":"griseofulvin-ultramicrocrystalline","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Alcoholism","Granulocytopenic disorder","Hepatic failure","Liver function tests abnormal","Lupus erythematosus and erythema multiforme-like syndrome","Porphyria","Pregnancy, function","Systemic lupus erythematosus"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT01518166","NCT00863863","NCT00117754","NCT00117767","NCT04318535","NCT00864071","NCT00127868"],"aliases":[],"company":"WYETH AYERST","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GRISEOFULVIN, ULTRAMICROCRYSTALLINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:47:09.535775+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:47:16.371053+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GRISEOFULVIN, ULTRAMICROCRYSTALLINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:47:17.095939+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tubulin inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:47:17.704066+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL562/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:47:17.595026+00:00"}},"allNames":"grisactin ultra","offLabel":[],"timeline":[],"brandName":"GRISACTIN ULTRA","ecosystem":[],"mechanism":{"target":"Lanosterol 14-alpha demethylase, Solute carrier family 22 member 1, Tubulin","novelty":"","modality":"Small Molecule","drugClass":"","explanation":"","oneSentence":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:47:19.519854+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://www.fda.gov/drugs","name":"FDA Drugs@FDA","fields":["phase","status","brandName","company"],"retrievedDate":"2026-04-07"},{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"GRISEOFULVIN, ULTRAMICROCRYSTALLINE","indications":{"approved":[{"name":"Onychomycosis due to dermatophyte","diseaseId":"onychomycosis-due-to-dermatophyte","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tinea barbae","diseaseId":"tinea-barbae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tinea capitis","diseaseId":"tinea-capitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tinea corporis","diseaseId":"tinea-corporis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tinea cruris","diseaseId":"tinea-cruris","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tinea pedis","diseaseId":"tinea-pedis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"currentOwner":"WYETH AYERST","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01518166","phase":"Phase 1","title":"A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","isPivotal":false,"enrollment":70,"indication":"Diabetes, Healthy","completionDate":"2007-04"},{"nctId":"NCT00863863","phase":"Phase 1","title":"A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Femal","status":"COMPLETED","sponsor":"Actavis Inc.","isPivotal":false,"enrollment":40,"indication":"Healthy","completionDate":"2006-01"},{"nctId":"NCT00117754","phase":"Phase 3","title":"Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis","status":"COMPLETED","sponsor":"Novartis","isPivotal":true,"enrollment":720,"indication":"Tinea Capitis","completionDate":"2006-04"},{"nctId":"NCT00117767","phase":"Phase 3","title":"Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":720,"indication":"Tinea Capitis","completionDate":""},{"nctId":"NCT04318535","phase":"Phase 1","title":"An Open Label, Randomized, Balanced, Three Treatment, Three Period, Three Sequence, Single Dose, Crossover Study to Evaluate the Bioequivalence of Test Griseofulvin Tablets, 500 mg Versus Reference Gr","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":36,"indication":"Antifungal Agents","completionDate":"2020-02-06"},{"nctId":"NCT00864071","phase":"Phase 1","title":"A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study Of Griseofulvin 125 mg/5 mL Suspension Versus Grifulvin V® 125 mg/5 mL Suspension In Normal, Healthy, Non-Smoking Male And Femal","status":"COMPLETED","sponsor":"Actavis Inc.","isPivotal":false,"enrollment":50,"indication":"Healthy","completionDate":"2005-11"},{"nctId":"NCT00127868","phase":"NA","title":"A Randomized, Double-Blinded, Placebo-Controlled Study Observing the Efficacy of Selenium Sulfide 1% Shampoo, Ketoconazole 2% Shampoo, and Ciclopirox 1% Shampoo as Adjunctive Treatments for Tinea Capi","status":"COMPLETED","sponsor":"Chen, Catherine, M.D.","isPivotal":false,"enrollment":47,"indication":"Tinea Capitis","completionDate":"2008-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"ORAL","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL562"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Dermatology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"companyName":"WYETH AYERST","companyId":"wyeth-ayerst","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1980-03-13T00:00:00.000Z","mah":"WYETH AYERST","brand_name_local":"GRISACTIN ULTRA","application_number":"ANDA062178"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1992-06-30T00:00:00.000Z","mah":"PLIVA","brand_name_local":"ULTRAGRIS-165","application_number":"ANDA062645"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1992-06-30T00:00:00.000Z","mah":"PLIVA","brand_name_local":"ULTRAGRIS-330","application_number":"ANDA062646"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:47:19.519854+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}